Sintilimab: all 353 studies that test it
Page 3 of 4. Open to participants first (182), then studies with results posted, then the rest; newest registration first within each.
- A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell CarcinomaStatus unknownNCT05749042Phase 2
- Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0348 in Advanced Solid TumorsTerminatedNCT05718219Phase 1
- IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract CancerStatus unknownNCT05653180Phase 1/2
- ASKB589 in Combination With CAPOX and PD-1 Inhibitors in Patients With Advanced, and Unresectable G/GEJ Cancer.Active, not recruitingNCT05632939Phase 1/2
- Multi-cohort Study of Surufatinib Plus Sintilimab in Metastatic NEN and Pancreatic Carcinoma Who Failed Standard ChemotherapyStatus unknownNCT05627427Phase 2
- Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric CancerStatus unknownNCT05627414Phase 2
- Fruquintinib Combined with Sintilimab As Second-line Therapy for Gastric or Gastro-esophageal Junction AdenocarcinomaActive, not recruitingNCT05625737Phase 2
- HAIC or Lenvatinib Combined With Sintilimab for High Recurrence Risk Resectable Solitary Hepatocellular CarcinomaActive, not recruitingNCT05621499Not applicable
- Combination Therapy of HAIC, Sintilimab and Bevacizumab for Advanced Hepatocellular CarcinomaStatus unknownNCT05617430Phase 2
- A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous MelanomaWithdrawnNCT05572463Phase 1/2
- Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLCCompletedNCT05549037Phase 3
- Sintilimab Combined With Regorafenib and HAIC in Patients With Colorectal Liver MetastasisStatus unknownNCT05524155Phase 2
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedNCT05522231Phase 2/3
- Surufatinib Combined With Sintilimab and AG in First-line Therapy of Patients With Locally Advanced or Metastatic Pancreatic CancerActive, not recruitingNCT05481476Phase 2
- Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBCStatus unknownNCT05386524Phase 2
- Phase I Study of Sintilimab in Healthy Chinese Male SubjectsCompletedNCT05337267Phase 1
- Radiotherapy in Combination With Sintilimab，GM-CSF and Fruquintinib in Patients With MSS mCRCStatus unknownNCT05292417Phase 2
- FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced StageStatus unknownNCT05279677Phase 2
- Radiofrequency Ablation Plus Systematic Neoadjuvant Therapy for Recurrent Hepatocellular Carcinoma (RANT Study)Status unknownNCT05277675Not applicable
- Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic CholangiocarcinomaStatus unknownNCT05251662Phase 2
- A Phase I Study of IBI325 in Patients With Advanced Solid TumorStatus unknownNCT05246995Phase 1
- Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLCActive, not recruitingNCT05244213Phase 2
- Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05220267Phase 2
- PD-1 Inhibitor Sintilimab Combined With Capecitabine for Adjuvant Treatment After Radical Resection of Cholangiocarcinoma.Status unknownNCT05207735Phase 2
- Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal MetastasisStatus unknownNCT05204173Phase 2
- Adjuvant Sintilimab Plus Capecitabine in Nasopharyngeal CarcinomaActive, not recruitingNCT05201859Phase 2
- Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell CarcinomaStatus unknownNCT05174325Phase 2
- Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal CancerActive, not recruitingNCT05171660Phase 3
- Donafenib Combine With Sintilimab and HAIC (Hepatic Artery Infusion Chemotherapy，HAIC）in the First-line Treatment of Unresectable Hepatocellular CarcinomaStatus unknownNCT05166772Phase 2
- Donafenib Plus Sintilimab for Advanced HCCCompletedNCT05162352Phase 2
- Sintilimab Combined With Chemotherapy and SBRT in Limited Metastatic Head and Neck Squamous Cell Carcinoma (LM-HNSCC)Status unknownNCT05136768Phase 2
- A Phase I Study of IBI325 in Patients With Advanced Solid TumorCompletedNCT05119998Phase 1
- IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)CompletedNCT05118334Phase 1
- Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung CancerActive, not recruitingNCT05116462Phase 3
- Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine NeoplasmStatus unknownNCT05113355Phase 2
- A Study of Sintilimab Combined With Concurrent Chemoradiation Therapy in Locally Advanced Cervical CancerStatus unknownNCT05105672Phase 2
- Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL)Status unknownNCT05039658Phase 1
- HAIC Combined With Sintilimab and Bevacizumab Biosimilar for Unresectable HCCStatus unknownNCT05029973Phase 2
- Cryoablation Combined with Sintilimab Plus Lenvatinib in Patients with Advanced Intrahepatic CholangiocarcinomaCompletedNCT05010668Phase 2
- Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLHStatus unknownNCT05008666Phase 2
- Safety and Efficacy of Sintilimab in Combination With Chemoradiothrapy Followed by D2 Surgical Resection in Patients With Advanced Gastric Cancer With Retroperitoneal Lymph Node MetastasisStatus unknownNCT05002686Phase 2/3
- Peri-operative Sintilimab in Combination With SOX in Locally Advanced Gastric CancerStatus unknownNCT04982939Phase 2
- A Phase II Study of Sintilimab Combined With Anlotinib in Treatment of ED-SCLCStatus unknownNCT04967625Phase 2
- TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)CompletedNCT04954794Phase 2
- IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPCCompletedNCT04945421Phase 1
- Neoadjuvant Safety of Sintilimab + XELOX + Bevacizumab in PMMR/MSS CRLM PatientsActive, not recruitingNCT04940546Phase 1/2
- Total Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal CancerActive, not recruitingNCT04906044Phase 1
- An Open-label, Single Arm, Phase II Trial of Niraparib in Combination With Anti-PD1（Programmed Cell Death Protein 1） Antibody in Recurrent/ Advanced Stage Endometrial Cancer PatientsStatus unknownNCT04885413Phase 2
- Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC.Status unknownNCT04882462Phase 2
- The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBCCompletedNCT04877821Phase 2
- Efficacy and Safety of Sintilimab Plus Bevacizumab in Metastatic Nasopharyngeal Carcinoma After Failure of Platinum-based Chemotherapy: An Open-label Phase II StudyStatus unknownNCT04872582Phase 2
- Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCCStatus unknownNCT04843943Phase 1/2
- cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven CriteriaCompletedNCT04842565Phase 2
- Stereotactic Ablation Radiotherapy Combined With Sintilimab in Early Inoperable Synchronous Multiple Primary Lung CancerStatus unknownNCT04840758Phase 1/2
- Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
- Study of Anlotinib Plus Sintilimab in the Treatment of Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04813406Not applicable
- PD-1 Inhibitor Concurrent With Chemotherapy as Neoadjuvant Therapy for TNBCStatus unknownNCT04809779Phase 2
- Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon MutationsCompletedNCT04790409Phase 2
- Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant MetastasisStatus unknownNCT04769908Phase 2
- Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell CarcinomaCompletedNCT04735861Phase 2
- A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCCompletedNCT04720716Phase 3
- Regorafenib Plus Sintilimab vs. Regorafenib as the Second-line Treatment for HCCStatus unknownNCT04718909Phase 2
- Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Oropharyngeal Squamous Cell CarcinomaActive, not recruitingNCT04718415Phase 2
- Phase II Trial of Fruquintinib With Sintilimab in Treating Selected Refractory Metastatic Colorectal Cancer PatientsStatus unknownNCT04695470Phase 2
- Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICCWithdrawnNCT04682249Phase 2
- Sintilimab Plus Bevacizumab as Adjuvant Therapy in HCC Patients at High Risk of Recurrence After Curative ResectionStatus unknownNCT04682210Phase 3
- A Study of Sintilimab Plus Ramucirumab as First-line Treatment for G/EGJ Adenocarcinoma (ORIENT-106)TerminatedNCT04675983Phase 3
- A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung CancerCompletedNCT04672356Phase 1
- Perioperative Therapy for Hepatocellular CarcinomaTerminatedNCT04653389Phase 2
- Neoadjuvant Immunotherapy to ESCCWithdrawnNCT04625543Phase 2
- HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTTCompletedNCT04618367Not applicable
- A Phase II Study of Anti-PD-1 Antibody, Sintilimab, as Second-line Therapy for Biomarker-selected Advanced or Metastatic NSCLCStatus unknownNCT04612673Phase 2
- Sintilimab Injection Combined With Concurrent CCRT in Locally Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04602013Phase 2
- Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC PatientsCompletedNCT04548440Phase 2
- The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal CancerStatus unknownNCT04535024Phase 2
- Sintilimab and Lenalidomide as a Treatment for CAEBVStatus unknownNCT04518982Phase 2
- A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCCStatus unknownNCT04514835Phase 2
- Sintilimab After Stereotactic Ablation Brachytherapy for Refractory Oligometastatic Non-Small Cell Lung CancerStatus unknownNCT04486287Phase 2
- Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE）Status unknownNCT04459611Phase 2
- A Study of Surufatinib Plus Sintilimab in Patients With Advanced Solid TumorTerminatedNCT04427774Phase 1
- Study on Sintilimab in Stage IV High Risk NeuroblastomaStatus unknownNCT04412408Early Phase 1
- Efficacy and Safety of IBI310 Combined with Sintilimab in Patients with Advanced Hepatocellular CarcinomaCompletedNCT04401813Phase 1
- Sintilimab in the Treatment of Advanced and Refractory Pediatric Malignant TumorsStatus unknownNCT04400851Phase 1
- Systemic Chemotherapy Plus PD-1 for Metastasis ICCWithdrawnNCT04398927Phase 2
- Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLCStatus unknownNCT04371796Phase 2
- The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue SarcomaStatus unknownNCT04356872Phase 2
- A Study Evaluating the Safety, Tolerability, and Initial Efficacy of Recombinant Human Anti-T-cell Immunoreceptor With Ig and ITIM Domains (TIGIT) Monoclonal Antibody Injection (IBI939) in Subjects With Advanced Malignant TumorsCompletedNCT04353830Phase 1
- PD-1 Monoclonal Antibody Combined With FLOT Regimen for Neoadjuvant Therapy of Gastric AdenocarcinomaStatus unknownNCT04341857Phase 2
- Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung CancerActive, not recruitingNCT04326153Phase 2
- Pd1 Antibody Sintilimab ± Chemoradiotherapy for Locally Advanced Rectal CancerActive, not recruitingNCT04304209Phase 2
- Sintilimab Plus Chidamide in the Treatment of Relapsed and Refractory Cutaneous T-cell Lymphoma: a Multicenter Phase II StudyStatus unknownNCT04296786Phase 2
- Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid TumorStatus unknownNCT04282278Phase 2
- Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell LymphomaStatus unknownNCT04279379Phase 2
- The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by SurgeryTerminatedNCT04277663Phase 3
- Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)CompletedNCT04271813Phase 2
- Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric CancerActive, not recruitingNCT04267549Phase 2
- Conversion Therapy With Sintilimab Plus CAPOX in Patients With Unresectable Locally Advanced or Limited Metastatic Adenocarcinoma of the Stomach or Esophagogastric JunctionStatus unknownNCT04263870Phase 2
- IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal CancerTerminatedNCT04258111Phase 2
- Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung CancerStatus unknownNCT04252365Phase 2
- Lenalidomide and Sintilimab for Relapsed/Refractory NK/T-cell LymphomaStatus unknownNCT04231370Phase 2